Hansoh Pharmaceutical Group Company Limited announced that Class 1 innovative drug "Tenofovir Amibufenamide Tablets" has been granted drug registration approval by the National Medical Products Administration of the People ' s Republic of China. The Product is an anti-infective drug indicated for the treatment of chronic hepatitis B virus infection in adults. The obtaining of drug registration approval of the Product will further enrich and improve the anti-infectives pipeline of the Group.